Advertisement
Screener

BioStem Technologies, Inc. (BSEM) Finance Lease, Right-of-Use Asset, Amortization

1.9 / 5 stars · 15/40 Roast Me

BioStem Technologies, Inc. Finance Lease, Right-of-Use Asset, Amortization

BioStem Technologies, Inc. (BSEM) reported Finance Lease, Right-of-Use Asset, Amortization of $106.72 thousand for the 6-month period ending 2026-06-30, per its S-1 filed 2026-09-18.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2026-09-18

Period endFinance Lease, Right-of-Use Asset, Amortization 6 monthFinance Lease, Right-of-Use Asset, Amortization 12 month
2026-06-30$106.72K
S-1 · filed 2026-09-18
2025-12-31$161.60K
S-1 · filed 2026-09-18
2025-06-30$53.56K
S-1 · filed 2026-09-18
2024-12-31$56.54K
S-1 · filed 2026-09-18

Similar stocks

Stock NameCountryMarket CapPE Ratio
CHAMPIONS ONCOLOGY, INC. (CSBR)United States$0.070B-68.02
Kalaris Therapeutics, Inc. (KLRS)United States$0.073B-2.19
Eloxx Pharmaceuticals, Inc. (ELOX)United States$0.065B
MiNK Therapeutics, Inc. (INKT)United States$0.063B-5.37
Vaxart, Inc. (VXRT)United States$0.080B3.84
EXOZYMES INC. (EXOZ)United States$0.058B
BioAtla, Inc. (BCAB)United States$0.058B-0.21
ImageneBio, Inc. (IMA)United States$0.056B-1.31
Inmune Bio, Inc. (INMB)United States$0.056B-2.48
Atara Biotherapeutics, Inc. (ATRA)United States$0.086B-6.48